Dr. Jacob Lalezari, MD - CEO, CytoDyn - Next Generation of Monoclonal Antibody Therapeutics

Dr. Jacob Lalezari, MD is the Chief Executive Officer of CytoDyn ( https://www.cytodyn.com/ ), a biopharma company committed to enhancing the lives of patients through target specific medicine and a next generation of monoclonal antibody therapeutics. CytoDyn’s team is focused on developing leronlimab, a monoclonal antibody CCR5 receptor antagonist, to be used as a platform drug for a variety of indications. 

Dr. Lalezari brings over 34 years of industry experience to CytoDyn, including nearly 20 years of experience with leronlimab, also known as PRO 140, and he previously served as interim CEO and Chief Medical Officer and has been a member of the Company’s scientific advisory board for the past several years.  

Dr. Lalezari has previously served as the CEO and Medical Director of Quest Clinical Research and served as the Chief Medical Officer of Virion Therapeutics. 

Dr. Lalezari has served as Principal Investigator for Phase I, II, and III clinical studies of new therapies for such viral diseases as HIV/AIDS, CMV, HPV, HSV, Hepatitis B and C, influenza, RSV, and COVID-19, including clinical trials conducted by the Company. His work has been published extensively and he is a well-regarded international speaker and patient advocate. 

Dr. Lalezari received his M.D. from the University of Pennsylvania, his M.A. from the University of Virginia, and his B.A. from the University of Rochester. He also holds a board certification from the American Board of Internal Medicine.

#JacobLalezari #Cytodyn #MonoclonalAntibody #Leronlimab #CCR5Receptor #CCR5Antagonist #ChemokineReceptor5 #HIV #AutoimmuneDisorders #HIVCoReceptor #Macrophages #DendriticCells #TripleNegativeBreastCancer #TLymphocytes #MetastaticColorectalCancer #PD1 #ProgrammedCellDeathProtein1 #Oncology #Immunooncology #Cancer #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research